Melbourne, Australia: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is today presenting at the Nomura Biotech Investment conference for institutional investors in Sydney.

Dr Fairley will present in detail Starpharma’s maturing development portfolio across sexual and women’s health, drug delivery and agrochemical programs.  Highlights of the presentation include:

VivaGel^® Bacterial Vaginosis program:  Starpharma is nearing its most significant milestone to date; the completion of two concurrent Phase 3 pivotal trials investigating VivaGel^® as a treatment for bacterial vaginosis (BV).  The company recently reported that it had passed already the halfway point for patient recruitment in these trials, with one now at 100 percent enrolment and the second now more than 70% enrolled.  In addition, recruitment is complete for the Phase 2 prevention of recurrence trial.  The Phase 3 treatment trials and the Phase 2 prevention trial are all expected to conclude later this year.

The completion of these pivotal Phase 3 trials will pave the way for Starpharma to seek regulatory approval for VivaGel^® as a treatment for BV.

Drug delivery program:  Starpharma’s drug delivery program is making excellent progress, with the company recently announcing that its program to improve the blockbuster chemotherapy, docetaxel, is advancing rapidly with clinical trials anticipated to commence in 2013.

In parallel, Starpharma is investigating how its technology can be applied to improve the delivery of a number of other major therapeutics, including the areas of antibodies and hormones.

Agrochemical program:  Starpharma’s work in the improvement of chemicals used in agriculture, like pesticides and herbicides, is progressing into new areas.  The lead candidate in Starpharma’s internal agrochemical program is an enhanced reformulation of the best-selling herbicide glyphosate (RoundUp^®), which has annual sales in excess of US$5 billion.

In addition, Starpharma is now is applying its dendrimer technology to selected other off-patent agrochemical agents with the potential to improve their performance and/or reduce or completely remove environmentally damaging solvents.

“We are pleased to have the opportunity to present Starpharma at this forum and to provide an update to investors on the rapid advancement across all three development programs supported by Starpharma, in particular the excellent progress on our pivotal trials for the treatment of bacterial vaginosis,” said Chief Executive Officer Dr Jackie Fairley.

Download ASX Announcement: Starpharma presenting at Nomura Biotech Investment Conference ( pdf file, 1MB)